Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
Clinical Breast Cancer|April 16, 2026
Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast CancerKyoo Hyun Kim, Joohyuk Sohn, Min Hwan Kim, et al.
Breast Cancer Research and Treatment|July 15, 2020
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancerAhrong Ham, Min Hwan Kim, Gun Min Kim, et al.
Breast Cancer Research and Treatment|August 14, 2019
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
Breast Cancer Research and Treatment|June 25, 2020
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancerAhrong Ham, Min Hwan Kim, Gun Min Kim, et al.
Plos One|April 19, 2017
Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancerSung Gwe Ahn, Jae-Hoon Lee, Hak Woo Lee, et al.
Plos One|March 25, 2015
Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implicationMin Hwan Kim, Soohyeon Lee, Ja Seung Koo, et al.
Clinical Breast Cancer|July 10, 2017
Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's PerspectiveSeo Hee Choi, Jun Won Kim, Jinhyun Choi, et al.
Plos One|October 3, 2012
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapyMinkyu Jung, Ja Seung Koo, Young Wha Moon, et al.
British Journal of Cancer|June 9, 2025
GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>/CD4<sup>+</sup> T cells and TILs in patients with locally advanced or metastatic solid tumoursGun Min Kim, Sojeong Kim, Myung Ah Lee, et al.
Frontiers in Oncology|June 21, 2021
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast CancerSoong June Bae, Jee Hung Kim, Sung Gwe Ahn, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Clinical Breast Cancer|April 16, 2026
Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast CancerKyoo Hyun Kim, Joohyuk Sohn, Min Hwan Kim, et al.
Breast Cancer Research and Treatment|July 15, 2020
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancerAhrong Ham, Min Hwan Kim, Gun Min Kim, et al.
Breast Cancer Research and Treatment|August 14, 2019
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
Breast Cancer Research and Treatment|June 25, 2020
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancerAhrong Ham, Min Hwan Kim, Gun Min Kim, et al.
Plos One|April 19, 2017
Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancerSung Gwe Ahn, Jae-Hoon Lee, Hak Woo Lee, et al.
Plos One|March 25, 2015
Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implicationMin Hwan Kim, Soohyeon Lee, Ja Seung Koo, et al.
Clinical Breast Cancer|July 10, 2017
Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's PerspectiveSeo Hee Choi, Jun Won Kim, Jinhyun Choi, et al.
Plos One|October 3, 2012
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapyMinkyu Jung, Ja Seung Koo, Young Wha Moon, et al.
British Journal of Cancer|June 9, 2025
GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>/CD4<sup>+</sup> T cells and TILs in patients with locally advanced or metastatic solid tumoursGun Min Kim, Sojeong Kim, Myung Ah Lee, et al.
Frontiers in Oncology|June 21, 2021
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast CancerSoong June Bae, Jee Hung Kim, Sung Gwe Ahn, et al.
Pageof 13